Remarkably, BX795 treatment not only reduced cellular apoptosis at the basal level but also under CCCP-induced apoptosis in the E50K hRGCs, making it a strong candidate for OPTN mutation-associated glaucoma neuroprotection therapy. This evidence concerns the gene OPTN and glaucoma.